AYTU vs SUPN vs TPVG vs PCRX vs INVA

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus 1. 8% for Aytu BioPharma, Inc. (AYTU). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x — a reasonable growth-adjusted valuation.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -97. 8% for Aytu BioPharma, Inc. (AYTU). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Aytu BioPharma, Inc. 's 1. 27β — meaning AYTU is approximately 911% more volatile than INVA relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus 1. 8% for Aytu BioPharma, Inc. (AYTU). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -20. 4% for Aytu BioPharma, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -11. 8% for AYTU. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 5x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 17. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

In this comparison, TPVG (17.

1% yield) pays a dividend. AYTU, SUPN, PCRX, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +94. 9%, AYTU: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AYTU (Healthcare) and SUPN (Healthcare) and TPVG (Financial Services) and PCRX (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AYTU is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; PCRX is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. TPVG pays a dividend while AYTU, SUPN, PCRX, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.